Skip to content
Corona Remedies logo

Corona Remedies

CORONA NSE
₹2,405.80 +134.20 (+5.91%)
P/E
74.09
View as Markdown
MCP
Close 4 Nov 2026 ₹2,405.80 +967.40 +67.3% since 15 Dec 2025
Start ₹1,438.40

Key Fundamentals

SmallcapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Standalone · TTM

ROCE
33.30%
Debt to Equity
0.22
EPS (TTM)
₹32.47
Book Value
₹131.64
Market Cap
—
P/E (TTM)
74.09
P/B
18.28
ROE
29.50%
Dividend Yield
0.44%
EBITDA
₹304 Cr
52W High
₹2,458.00
52W Low
₹1,336.60
Day Range
₹2,271.70 – ₹2,458.00
Volume
2,00,640

Peer Comparison

Healthcare › Pharmaceuticals

Corona Remedies peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Corona Remedies (this company)
₹2,405.8074.09₹14,025 Cr18.280.44%29.50%33.30%₹1,479 Cr₹198 Cr
Median 8 companies₹2,048.6056.45₹1,25,337 Cr7.290.51%17.40%19.15%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

56 Good

Data confidence 100/100

Category scores

Quality
57
Good
Returns, margins, earnings quality 22% weight
Valuation
23
Poor
Cheap vs sector & own history 24% weight
Growth
54
Average
Sales & profit trajectory 9% weight
Financial Health
68
Strong
Solvency, leverage, coverage 9% weight
Momentum
74
Strong
Trend strength, vol-adjusted 12% weight
Ownership
77
Strong
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company has delivered good profit growth of 23.3% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 26.5%
  • Company has been maintaining a healthy dividend payout of 29.4%

Weaknesses

2
  • Stock is trading at 16.8 times its book value
  • Company might be capitalizing the interest cost

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish4312
OscillatorsBearish432
Moving AveragesStrong Bullish0010

Key readings

RSI (14)
74.70
Bearish
MACD (12,26,9)
50.29
Bullish
SMA (50)
2,109.33
Bullish
SMA (200)
1,835.83
Bullish

As of

Analyst Rating

Based on 2 analysts
BUY100%

2 of 2 analysts rate Buy, 0 Hold, 0 Sell.

As of

BUY
2
100%
HOLD
0
0%
SELL
0
0%

Growth Rate

From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
5Y+19.49%
3Y+16.65%
1Y+17.31%
TTM+17.96%

Net profit

Net profit growth by window
5Y+21.45%
3Y+29.59%
1Y+24.16%
TTM+20.00%

Operating cash flow

Operating cash flow growth by window
5Y+23.72%
3Y+30.52%
1Y+20.53%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
5Y+2.73 pp
3Y+6.48 pp
1Y+0.81 pp
TTM+0.63 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2019₹509 Cr
Mar 2020₹601 Cr
Mar 2021₹576 Cr
Mar 2022₹617 Cr
Mar 2023₹884 Cr
Mar 2024₹1,014 Cr
Mar 2025₹1,196 Cr
Mar 2026₹1,403 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2019₹35.00 Cr
Mar 2020₹59.00 Cr
Mar 2021₹70.00 Cr
Mar 2022₹0.00 Cr
Mar 2023₹85.00 Cr
Mar 2024₹90.00 Cr
Mar 2025₹149 Cr
Mar 2026₹185 Cr

Analyst Forecasts

Forecast For
FY27 consensus · EBITDA
₹366 Cr +20.5% vs FY26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 4 Nov 2026
AI opinion · based on fundamentals
Risk high

Corona Remedies Ltd trades at ₹2,405.8 as of 2026-11-04 with a market cap of ₹14,025.23 crore. The company combines strong profitability metrics — a 24.79% ROE and 29.31% ROCE — with low leverage at a debt-to-equity of 0.22, though the stock commands a premium valuation at a P/E of 74.09 and P/B of 18.28.

Bull Case 8
  • Compounded profit growth of 33% over the last 3 years and 23% over 5 years signals consistent and accelerating earnings expansion
  • ROE of 24.79% (with a 3-year average of 26% and last year at 30%) indicates efficient capital allocation well above cost of equity for most Indian firms
  • ROCE of 29.31% reflects strong operating returns on total capital employed, suggesting durable competitive advantages in its product portfolio
  • Debt-to-equity of just 0.22 provides a near-debt-free balance sheet, reducing financial risk and preserving flexibility for future growth investments
  • TTM sales growth of 18% and 5-year compounded sales growth of 19% demonstrate sustained top-line momentum across market cycles
  • Healthy dividend payout ratio of 29.4% alongside a 0.44% dividend yield shows shareholder-friendly capital return even while reinvesting for growth
  • The stock is trading near its 52-week high of ₹2,458, up approximately 80% from its 52-week low of ₹1,336.6, reflecting strong market confidence in the business trajectory
  • TTM profit growth of 28% continues to outpace TTM sales growth of 18%, indicating improving operating leverage or margin expansion
Bear Case 6
  • Price-to-book of 18.28 means investors are paying a steep premium over net asset value, amplifying downside risk in a market correction
  • Potential capitalisation of interest costs, if confirmed, would overstate reported profits and inflate ROE and ROCE metrics that currently appear attractive
  • With an EPS of ₹32.47 against a price of ₹2,405.8, the stock requires sustained high-growth execution for many years to grow into its current valuation
  • Dividend yield of 0.44% offers minimal income cushion, meaning total returns are almost entirely dependent on continued share price appreciation
  • A market cap of ₹14,025.23 crore for a pharmaceutical company with these revenue growth rates implies the market is pricing in flawless execution with little room for operational missteps
  • While 5-year compounded sales growth stands at 19%, profit growth outpacing revenue growth at 23% may not be sustainable if margin expansion reaches a ceiling

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

9h ago

TL;DR: Corona Remedies is expanding its international regulatory footprint with a third major GMP certification, positioning itself to tap Brazil's large pharma market, though India still drives over 96% of revenue. The NPPA demand notice of ~₹4.88 crore introduces minor regulatory overhang but the company downplays material impact. The trend is cautiously positive as export optionality grows, but near-term revenue concentration in India and pricing regulation risks warrant monitoring.

Headwinds 1
  • ₹4.88 Cr NPPA demand notice Nov 3

    Corona Remedies received a ₹4,87,97,160 demand notice alleging violation of Para 15 of DPCO 2013 regarding price approvals, including interest and penalty components. The company asserts no material financial impact, but regulatory scrutiny on drug pricing remains a risk.

Positives 1
  • ANVISA GMP for Brazil exports Oct 22

    Secured ANVISA GMP certification for OSD and hormone facilities in Ahmedabad, marking the third major international GMP accreditation after EU and EAEU. Opens access to Brazil's estimated $44 billion pharma market for export growth.

Quarterly Results

₹ Cr
CORONA quarterly results, ₹ crore
Particulars Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
314
298
294
347
361
342
353
422
441
Expenses
247
228
239
277
283
259
291
329
345
Operating Profit
67
69
54
70
78
83
62
93
96
OPM %
21%
23%
18%
20%
22%
24%
18%
22%
22%
Other Income
2
1
1
2
2
−17
4
3
2
Interest
3
2
2
2
2
2
1
3
3
Depreciation
9
10
10
9
9
9
10
13
15
PBT
57
58
43
61
70
55
54
80
81
Tax %
25%
23%
28%
24%
25%
25%
17%
25%
25%
Net Profit
43
45
31
46
52
41
45
60
60
EPS (₹)
7.03
7.32
5.12
7.59
8.53
6.74
7.37
9.83
—

Sep 2026: from the results filed on 30 Oct 2026, ahead of the full statement, so some rows are blank.

Profit & Loss

₹ Cr
CORONA profit and loss, annual, ₹ crore
Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
509
601
576
617
884
1,014
1,196
1,403
1,479
Expenses
444
509
471
600
756
859
956
1,109
1,162
Operating Profit
66
93
105
18
128
156
241
294
317
OPM %
13%
15%
18%
2.9%
14%
15%
20%
21%
21%
Other Income
3
3
5
7
7
5
5
−9
−7
Interest
1
2
2
5
4
14
11
7
8
Depreciation
14
16
16
20
20
28
37
38
42
PBT
54
77
92
−1
111
118
198
240
260
Tax %
35%
24%
24%
−49%
23%
24%
25%
23%
—
Net Profit
35
59
70
0
85
90
149
185
199
EPS (₹)
6.8
11.51
13.69
−0.08
13.85
14.8
24.37
30.22
32.47
Div. Payout %
0%
0%
0%
0%
20%
25%
30%
33%
—

Balance Sheet

₹ Cr
CORONA balance sheet, annual, ₹ crore
Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
5
5
5
51
61
61
61
61
Reserves
204
263
333
270
347
419
545
685
Borrowings
13
47
50
34
28
159
86
165
Other Liabilities
71
94
144
157
159
191
237
293
Total Liabilities
293
408
532
511
595
830
929
1,204
Fixed Assets
80
81
164
162
185
384
370
554
CWIP
4
42
0
14
65
121
186
143
Investments
9
7
37
14
31
25
25
25
Other Assets
200
278
330
321
314
301
348
482
Total Assets
293
408
532
511
595
830
929
1,204

Cash Flow

₹ Cr
CORONA cash flow, annual, ₹ crore
Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
19
43
79
98
103
157
190
229
Investing
−23
−50
−102
−66
−50
−267
−84
−256
Financing
4
30
0
−30
−45
99
−107
25
Net Cash Flow
−1
23
−23
2
8
−11
0
−1
Free Cash Flow
19
1
6
64
9
−129
99
56
CFO/EBITDA
49
65
101
557
100
112
97
95

Ratios

CORONA financial ratios, annual
Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
95
105
131
44
36
36
36
38
Inventory Days
69
52
77
184
182
158
200
175
Days Payable
126
110
182
211
163
184
221
206
Cash Conversion Cycle
38
48
27
17
55
10
14
7
Working Capital Days
67
81
86
16
30
−2
9
−15
ROCE %
—
30%
27%
1%
29%
25%
31%
33%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Corona Remedies insights

70 extracted metrics across FY19–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 69.00%
  • DIIs 16.45%
  • Others 9.31%
  • FIIs 4.21%
  • Public 1.03%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Corona Remedies

What does Corona Remedies Ltd do?
Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management, urology, and other therapeutic areas.
Where is Corona Remedies Ltd (CORONA) listed?
Corona Remedies Ltd trades as CORONA on the NSE and under code 544644 on the BSE.
Which sector does Corona Remedies Ltd belong to?
Corona Remedies Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Corona Remedies Ltd?
Corona Remedies Ltd trades at a PE ratio of 74.09 as of 4 Nov 2026, on earnings per share of ₹32.47, against a book value of ₹131.64 per share.
What is the 52-week high and low of Corona Remedies Ltd?
Over the last 52 weeks Corona Remedies Ltd has traded between ₹1,336.6 and ₹2,458 as of 4 Nov 2026.
Does Corona Remedies Ltd pay dividends?
Corona Remedies Ltd has a dividend yield of 0.44%.
What is the Return on Equity (ROE) of Corona Remedies Ltd?
Corona Remedies Ltd reported a return on equity of 29.50%. Its debt-to-equity ratio is 0.22.

Company Information

Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management, urology, and other therapeutic areas.

Website coronaremedies.com
CEO Mr. Niravkumar Kirtikumar Mehta
Employees 4,500
Listed 15 Dec 2025
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/CORONA.md for Corona Remedies Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month